§ 522.542  Dexamethasone-21-isonicotinate suspension.

(a) Specifications. Each milliliter of sterile suspension contains 1 milligram of dexamethasone-21-isonicotinate.

(b) Sponsor. No. 000010 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is used in the treatment of various inflammatory conditions associated with the musculoskeletal system in dogs, cats, and horses.

(2) It is recommended for intramuscular administration as follows: Dogs—0.25 to 1 milligram; cats—0.125 to 0.5 milligram; horses—5 to 20 milligrams. Dosage may be repeated.

(3) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition following by dystocia, fetal death, retained placenta, and metritis.

(4) Not for use in horses intended for food.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.558  Dexmedetomidine.

(a) Specifications. Each milliliter of solution contains 0.5 milligram (mg) of dexmedetomidine hydrochloride.

(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Indications for use and amount. (A) For use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures; and as a preanesthetic to general anesthesia.

(ii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b) Cats—(i) Amount. 40 μg/kilogram by intramuscular injection.

(ii) Indications for use. For use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures; and as a preanesthetic to general anesthesia.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.563  Diatrizoate meglumine and diatrizoate sodium injection.

(a) Specifications. Diatrizoate meglumine and diatrizoate sodium injection contains 34.3 percent diatrizoate meglumine and 35 percent diatrizoate sodium, or 66 percent diatrizoate meglumine and 10 percent diatrizoate sodium, in sterile aqueous solution.

(b) Sponsor. See No. 053501 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) It is indicated for use in dogs and cats for visualization in excretion urography, including renal angiography, uretography, cystography, and urethography; aortography; angiocardiography, peripheral arteriography, and venography; selective coronary arteriography; cerebral angiography; lymphography; arthrography; discography; and sialography. It is also useful as an aid in delineating peritoneal hernias and fistulous tracts.

(2) For excretion urography administer 0.5 to 1.0 milliliter per pound of body weight to a maximum of 30 milliliters intravenously. For cystography remove urine, administer 5 to 25 milliliters directly into the bladder via catheter. For urethrography administer 1.0 to 5 milliliters via catheter into the urethra to provide desired contrasts delineation. For angiocardiography (including aortography) rapidly inject 5 to 10 milliliters directly into the heart via catheter or intraventricular puncture. For cerebral angiography rapid injection of 3 to 10